Cancer of Unknown Primary Site
📧 Sign up to get email alerts when something new happens for Cancer of Unknown Primary Site.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: 18F-FAPI PET in Cancers of Unknown Primary Site
Clinical trial update on using 18F-FAPI PET imaging in cancers of unknown primary site. The study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Trial of Pembrolizumab in Cancer of Unknown Primary [Phase 2]
A Phase 2 trial evaluating pembrolizumab in cancer of unknown primary site has completed.
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: TCF-001 TRACK (Target Rare Cancer Knowledge) Study [NA]
Clinical trial update for TCF-001 TRACK study (Target Rare Cancer Knowledge) is currently recruiting. The study targets cholangiocarcinoma a…
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site [Phase 2]
Phase II randomized study comparing targeted therapy or cancer immunotherapy against platinum-based chemotherapy in cancer of unknown primar…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine [Phase 2]
Phase 2 trial comparing cardiovascular side effects of Teysuno versus capecitabine in gastrointestinal cancers completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-01-24Clinical Trial Update: Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary [Phase 3]
Phase 3 clinical trial update for Tissue-of-origin Directing Therapy in Cancer of Unknown Primary Site has completed.
-
CLINICAL_TRIALS trial_result · 2020-04-15Clinical Trial Update: Nivolumab/Ipilimumab in Second Line CUP-syndrome [Phase 2]
Phase 2 clinical trial update evaluating nivolumab/ipilimumab in second-line cancer of unknown primary site.